Phase I HALO Study to Use Biomarkers and Machine Learning for Earlier and More Accurate Diagnosis of Cardiovascular, Cancer, Neurologic, and Other Diseases in Men Aged 45 to 90

What this Trial Is About

Researchers are conducting the Phase I Human Analytics HALO Study to improve diagnosis and risk prediction for cardiovascular diseases, cancer, dementia, traumatic brain injury, and other disorders. The study uses machine learning and data analysis techniques on electronic medical records to detect subtle patterns, aiming to diagnose diseases earlier and more accurately. The research also focuses on developing multivariate biomarker risk scores and directing participants to relevant clinical trials based on physician review. This observational study involves no interventions and includes groups of patients diagnosed with dementia, prostate cancer, breast cancer, traumatic brain injury, and patients without any diagnosed condition. Data analysis will be applied to all available biomarkers and health determinants to enhance diagnostic confidence and reduce time to diagnosis. Participants are observed over time, with no treatments administered as part of the study. Participants will be monitored through clinical evaluations, biomarker assessments, and data analysis to assess prostate cancer staging, Gleason scores, and mortality over up to five years. Additional outcomes include measurements of urinary symptoms, erectile function, emotional well-being, and incontinence levels. The study collects comprehensive health data to improve diagnosis and risk stratification, with participant involvement lasting several years for long-term monitoring and evaluation.

Phase I Human Analytics (HALO) Study